Pharmaron vs SK pharmteco: CDMO Comparison
How does Pharmaron compare to SK pharmteco for AAV manufacturing?
Side-by-side comparison of Pharmaron and SK pharmteco on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Pharmaron has more FDA inspections on record (5 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Pharmaron maintains 1 MHRA / UK GMP certificate; SK pharmteco does not.
On a 13-modality CDMO landscape, both Pharmaron and SK pharmteco qualify as AAV manufacturers; Pharmaron carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Pharmaron and SK pharmteco qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Pharmaron vs SK pharmteco
How does Pharmaron compare to SK pharmteco for AAV manufacturing?
On CDMO Signal's composite Signal Score, Pharmaron is 87/100 and SK pharmteco is 80/100; Pharmaron has 5 FDA inspections on record vs 0 for SK pharmteco; European coverage is 1 active EMA+MHRA certificate for Pharmaron vs 0 for SK pharmteco. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Pharmaron or SK pharmteco?
Both Pharmaron and SK pharmteco maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Pharmaron has 5 FDA inspections on record; SK pharmteco has 0.
How do Pharmaron and SK pharmteco compare on European GMP coverage?
Pharmaron holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. SK pharmteco holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for AAV manufacturing — Pharmaron or SK pharmteco?
Both Pharmaron and SK pharmteco are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Pharmaron carries a Signal Score of 87/100 and SK pharmteco carries 80/100 — a small lead for Pharmaron. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →